Fideuram Asset Management Ireland dac Invests $413,000 in Royalty Pharma PLC $RPRX

Fideuram Asset Management Ireland dac bought a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX) in the fourth quarter, HoldingsChannel reports. The institutional investor bought 10,795 shares of the biopharmaceutical company’s stock, valued at approximately $413,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Lloyd Advisory Services LLC. bought a new stake in shares of Royalty Pharma during the fourth quarter worth $30,000. Private Trust Co. NA raised its position in shares of Royalty Pharma by 52.9% during the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 288 shares during the last quarter. Smartleaf Asset Management LLC raised its position in shares of Royalty Pharma by 868.1% during the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 790 shares during the last quarter. Larson Financial Group LLC raised its position in shares of Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 306 shares during the last quarter. Finally, Fifth Third Bancorp raised its position in shares of Royalty Pharma by 16.9% during the third quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 362 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, EVP Marshall Urist sold 13,684 shares of the stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $52.75, for a total value of $721,831.00. Following the completion of the sale, the executive vice president directly owned 18,197 shares in the company, valued at $959,891.75. This represents a 42.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of the stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.00, for a total value of $161,385.00. Following the completion of the sale, the director owned 191,803 shares of the company’s stock, valued at $10,165,559. This trade represents a 1.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 199,185 shares of company stock worth $10,082,926. 18.84% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on RPRX shares. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Weiss Ratings downgraded Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 15th. Citigroup boosted their target price on Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. upped their price objective on Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Finally, UBS Group upped their price objective on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $53.71.

Royalty Pharma Stock Performance

NASDAQ RPRX opened at $55.76 on Monday. The stock has a 50-day simple moving average of $49.89 and a 200 day simple moving average of $44.50. The company has a market capitalization of $32.11 billion, a PE ratio of 37.93, a P/E/G ratio of 1.53 and a beta of 0.43. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. Royalty Pharma PLC has a 12 month low of $32.29 and a 12 month high of $56.07.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. The business had revenue of $630.58 million during the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. Research analysts forecast that Royalty Pharma PLC will post 5.05 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Friday, May 15th. Royalty Pharma’s dividend payout ratio is currently 63.95%.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.